Zilovertamab vedotin is an experimental treatment given through an intravenous infusion (a liquid medicine delivered directly into your vein) to see if it can effectively treat certain types of B-cell cancers.

Nemtabrutinib is an experimental medicine taken by mouth in tablet form. In this study, it is being tested both on its own and combined with another medication to see how well it works and how safe it is for people with specific blood cancers.

Mantle cell lymphoma – This is a type of blood cancer that starts in the B cells of the immune system. It typically develops in the lymph nodes and can spread to other parts of the body like the bone marrow or spleen. The disease can grow quickly or more slowly depending on the specific characteristics of the cells. It involves an abnormal accumulation of these cancerous cells within the lymphatic system.

Chronic lymphocytic leukemia – This is a slow-growing cancer of the blood and bone marrow. It occurs when the body produces too many abnormal white blood cells called lymphocytes. These cells build up in the blood and lymphatic system over time. The condition often progresses gradually, sometimes remaining stable for long periods.

Follicular lymphoma – This is a slow-growing type of non-Hodgkin lymphoma that originates in the lymph nodes. It is characterized by the formation of small groups of cells called follicles. The disease typically progresses at a very gradual pace. Over time, the cancerous cells can spread to different parts of the lymphatic system.

Richter’s syndrome – This condition occurs when a previously existing slow-growing type of lymphoma, such as chronic lymphocytic leukemia, changes into a much more aggressive form. The disease shifts from a slow progression to a much faster and more rapid growth pattern. This transformation results in a significant change in how the cancer cells behave within the body.